Since a-MSH suppresses endotoxin-induced inflammation by innate immunity, it is possible that a-MSH can suppress the interface between innate and adaptive immunity mediated by TLR4-stimulated macrophages. Endotoxin-stimulated macrophages treated with a-MSH are suppressed in nitric oxide and IL-12p70 production, and cannot enhance antigen-stimulated IFN-g production by Th1 cells. In macrophages treated with a-MSH, the inhibitory molecule IRAK-M is bound to IRAK-1, the proximal intracellular signal molecule of endotoxin-bound TLR4. These results further demonstrate the dynamic contribution of the nervous system, and the role of a-MSH in modulating the innate and adaptive immune interface in an inflammatory response. D
Introduction
The neuropeptide alpha-melanocyte-stimulating hormone (a-MSH), a 13-amino acid-long peptide derived from the proteolytic cleavage of proopiomelnocotin hormone (Chakraborty et al., 1996; Lee et al., 1961) , is well documented to be a potent suppressor of endotoxin-, IL-1-, and TNFmediated inflammation (Lipton and Catania, 1997) . Systemic injections of a-MSH suppress septic shock, and fever. The treatment of mice with a-MSH at the time of haptensensitization causes antigen presenting cells (APC) to prime immunity devoid of a hypersensitivity response (Grabbe et al., 1996) . Through melanocortin 1 and melanocortin 3 receptors on macrophages, a-MSH suppresses endotoxin activation of p38 MAPK and NF-nB (Getting et al., 2003; Ichiyama et al., 1999; Yoon et al., 2003 ). There is a constitutive level of a-MSH in various body tissues and fluids, and in response to a systemic inflammatory response there is an elevation of its concentration in blood (Holdeman et al., 1985; Taylor and Streilein, 1996; Taylor et al., 1992) .
For the past decade we have examined the role of a-MSH in ocular regional immunity (Taylor, 2003b) . The ocular microenvironment is a tissue site where local mechanisms of suppression barricade the activation of inflammatory immunity. This regional immunity was first experimentally observed by Medawar and his colleagues in the 1940s where they describe the prolong survival of incompatible grafts placed into the anterior chamber of the eye (Medawar, 1948) . This immunosuppression is considered an evolutionary adaptation to prevent vision loss caused by the irreversible collateral tissue damage of autoimmune disease and delayed-type hypersensitivity (Streilein, 2003) . The unique regulation of immunity in the eye is mediated in part by factors produced and expressed within the ocular microenvironment. The nervous system is a significant contributor of these immunosuppressive factors (Taylor, 2003a) . The neurological contribution is characterized by the selective and con-
